

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## CHINA HEALTH

China Health Technology Group Holding Company Limited

中國健康科技集團控股有限公司

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1069)**

- (1) RE-DESIGNATION OF A DIRECTOR**
- (2) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR**
- (3) CHANGE IN COMPOSITIONS OF THE BOARD COMMITTEES**

### **RE-DESIGNATION OF A DIRECTOR**

The board (the “**Board**”) of directors (the “**Director(s)**”) of China Health Technology Group Holding Company Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) announces that Ms. Bu Xue (“**Ms. Bu**”), an independent non-executive Director, has been re-designated as an executive Director with effect from 1 April 2025.

The biography of Ms. Bu is as follows:

Ms. Bu Xue, aged 36, obtained her Bachelor’s degree in Business Administration from Zhengzhou University of Aeronautics in July 2011. She has attained the accounting professional qualification issued by Ministry of Human Resources and Social Security and Ministry of Finance of the People’s Republic of China since September 2020 and has attained the qualification of tax advisor issued by The China Certified Tax Agents Association since December 2022. She has over ten years of experience in marketing and business development.

Save as disclosed above, as at the date of this announcement, Ms. Bu (i) does not hold any other position with the Company or other members of the Group; (ii) does not have any relationship with the Directors, senior management, substantial or controlling shareholders (as defined in the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)) of the Company; (iii) has not held any directorship in any other public companies in the last three years, the securities of which are listed on any securities market in Hong Kong or overseas or other major appointments and professional qualifications; and (iv) does not have any interests in the shares, underlying shares and debentures of the Company which are required to be disclosed pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

Save as disclosed above, there is no other information which is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the re-designation of Ms. Bu that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) in relation to her re-designation.

With respect to the re-designation of her directorship with the Company, Ms. Bu has entered into a contract of appointment with the Company and Ms. Bu will be appointed for a term of one year with an annual remuneration of HK\$96,000. The remuneration is recommended by the remuneration committee of the Board (the “**Remuneration Committee**”) with reference to the remuneration policy of the Company, her duties and the prevailing market level of remuneration for executives of similar positions. Ms. Bu shall only hold office until the next annual general meeting of the Company but shall be eligible for re-election in accordance with the articles of association of the Company.

## **APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR**

The Board is pleased to announce that Ms. Liu Shuhua (“**Ms. Liu**”) has been appointed as an independent non-executive Director and a member of each of the audit committee of the Board (the “**Audit Committee**”), the Remuneration Committee and the nomination committee of the Board (the “**Nomination Committee**”) with effect from 1 April 2025.

Biographic details of Ms. Liu are set out as follows:

Ms. Liu Shuhua, aged 56, graduated from Henan University of Finance and Law (河南財經政法大學) in 1993 with a bachelor’s degree in law, and holds a lawyer’s qualification certificate in the People’s Republic of China. Ms. Liu has extensive experience in legal professional services and business management. She had served as the permanent legal adviser and investment adviser of a number of large-scale state-owned enterprises and joint-stock companies. She worked in Henan Chengda Law Firm (河南誠達律師事務所) from 1989 to 2004, served as the legal adviser of Henan Jianye Group (河南建業集團) from 2004 to 2022, and has served as the chairman of the board of directors of Beijing Xianghua Yongxin Technology Co., Ltd. (北京祥華永信科技有限公司) since 2023.

Save as disclosed above, as at the date of this announcement, Ms. Liu (i) does not hold any other position with the Company or other members of the Group; (ii) does not have any relationship with the Directors, senior management, substantial or controlling shareholders (as defined in the Listing Rules) of the Company; (iii) has not held any directorship in any other public companies

in the last three years, the securities of which are listed on any securities market in Hong Kong or overseas or other major appointments and professional qualifications; (iv) does not have any interests in the shares, underlying shares and debentures of the Company which are required to be disclosed pursuant to Part XV of SFO; and (v) has also confirmed that she has met the independence criteria as set out in Rule 3.13 of Listing Rules, she has no past or present financial or other interests in the business of the Company or its subsidiaries or any connection with any core connected person (as defined in the Listing Rules), and there are no other factors which might affect her independence as at the date of this announcement.

Save as disclosed above, the Board is not aware of other matters relating to the appointment of Ms. Liu that need to be brought to the attention of the shareholders of the Company and there is no other information which is required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules.

With respect to her directorship with the Company, Ms. Liu has entered into a contract of appointment with the Company and Ms. Liu will be appointed for a term of one year with an annual remuneration of HK\$36,000. The remuneration is recommended by the Remuneration Committee with reference to the remuneration policy of the Company, her duties and the prevailing market level of remuneration for executives of similar positions. Ms. Liu shall only hold office until the next annual general meeting of the Company but shall be eligible for re-election in accordance with the articles of association of the Company.

The Board would like to extend its warmest welcome to Ms. Liu for her appointment.

## **CHANGE IN COMPOSITIONS OF THE BOARD COMMITTEES**

The Board also announces the following changes in the compositions of the Board committees with effect from 1 April 2025:

- (i) Ms. Bu ceased to be a member of each of the Audit Committee, the Remuneration Committee and the Nomination Committee; and
- (ii) Ms. Liu has been appointed as a member of each of the Audit Committee, the Remuneration Committee and the Nomination Committee.

By Order of the Board  
**China Health Technology Group Holding Company Limited**  
**Professor Fei Phillip**  
*Chairman and Executive Director*

Hong Kong, 1 April 2025

*As at the date of this announcement, the Board comprises Professor Fei Phillip, Mr. Wang Yibin and Ms. Bu Xue as the executive Directors; and Mr. Guo Zhonglong, Mr. Chau Wing Nam and Ms. Liu Shuhua as the independent non-executive Directors.*